Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit
08 déc. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for...
Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
01 déc. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Bio to Participate in Upcoming Investor Conferences
06 nov. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update
05 nov. 2020 16h10 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer
26 oct. 2020 16h10 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy
22 oct. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio to Present at the Jefferies Cell Therapy Summit
01 oct. 2020 16h10 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio, Inc. Determines Not to Proceed with Public Offering of Common Stock
22 sept. 2020 22h42 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock
21 sept. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...
Adicet Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
18 sept. 2020 16h10 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...